Navigation Links
Added benefit of linagliptin is not proven
Date:1/6/2012

Linagliptin (trade name: Trajenta) has been approved since August 2011 to improve blood glucose control ("glycaemic control") in adults with type 2 diabetes mellitus whose elevated blood glucose levels are inadequately controlled by diet and exercise. It is an option for patients who do not tolerate or should not take the usual treatment with the drug metformin. Moreover, linagliptin can be added if treatment with metformin alone is not sufficient.

In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether linagliptin offers an added benefit versus the appropriate comparator therapy specified by the Federal Joint Committee (G-BA). No such added benefit can be inferred from the dossier, as the drug manufacturer deviated from the G-BA's specifications and chose a different comparator therapy.

Approval status distinguishes between three treatment situations

The appropriate comparator therapy specified by the G-BA distinguishes between three treatment situations:

* Administration of linagliptin alone (monotherapy) as a substitute for metformin if this drug is not tolerated by patients or should not be taken because of impaired kidney function. To assess the added benefit, linagliptin monotherapy should be compared with a drug from the sulfonylurea class (glibenclamide or glimepiride).

* Dual therapy combines linagliptin and metformin and is indicated if treatment with metformin alone is insufficient to control blood glucose levels. To assess the added benefit, dual therapy with linagliptin should be compared with a combination of metformin and a sulfonylurea (glibenclamide or glimepiride).

* Triple therapy combines linagliptin, metformin and a sulfonylurea and is used if dual therapy with metformin and a sulfonylurea is no longer a sufficient treatment option. To assess the added benefit, triple therapy should be compared with a combination of insulin and metformin.

Drug manufacturer chose a gliptin as comparator therapy

In its dossier, the manufacturer compared linagliptin with a different drug from the gliptin class (sitagliptin) in all three treatment situations and thereby deviated from the specifications of the G-BA. However, in IQWiG's opinion, the manufacturer insufficiently justified this deviation. For the dossier assessment IQWiG therefore uses the appropriate comparator therapy specified by the G-BA.

In the dossier, the manufacturer makes no statements on the extent and probability of an added benefit of linagliptin versus the appropriate comparator therapy specified by the G-BA. Studies that would have been relevant for this purpose were explicitly excluded from the assessment. The manufacturer's dossier therefore provides no proof of an added benefit of linagliptin versus the G-BA's appropriate comparator therapy. This applies to all three treatment situations mentioned above, that is, monotherapy, dual and triple combination therapy.

In the dossier the manufacturer did not determine an added benefit of linagliptin versus the comparator therapy they had chosen themselves (sitagliptin).

G-BA decides on the extent of added benefit

The procedure for inferring the overall conclusion on the extent of added benefit is a proposal from IQWiG. The G-BA, which has opened a formal commenting procedure, will decide on the extent of added benefit.


'/>"/>
Contact: Anna-Sabine Ernst
presse@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. Repeated Weight-Loss Surgery Carries Added Risks
2. Added Drug Aids MS Treatment
3. Breast cancer screening: No added value through mammography
4. Employee Donations for Haiti Relief Matched by Capital BlueCross, Added to Corporate Contribution
5. Licorice Flavonoid Oil with Glavonoid™ Added to the Swanson Health Products' Swanson Best Weight-Control Formulas
6. Microwize Technology is Recognized as the Best Support Value Added Reseller (VAR) for Lytec Medical Billing Software
7. Added Sugars in Diet Threaten Heart Health
8. LifeLinks Revolutionizes Video Interpreting, Shows Spanish Interpreting in Added Dimension-VIDEO!
9. Genetic data added to archaeology and linguistics to get picture of African population history
10. FileHold Document Management Software welcomes Click2ScanLtd. as a Value Added Re-sellers in the UK
11. More Natural Fat Burning Foods & Ready-Made Meal Plans Added to the Newly Revised Version of The Diet Solution Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... , ... Sharon Kleyne, host of the nationally syndicated radio program, The Sharon ... America, declared on her radio program in November 2016 the need to educate people ... attack leaders in corporate America, they are trying to take advantage of successful algorithms ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Facial plastic ... this holiday season by donating a portion of proceeds to two local organizations: North ... Chicago Animal Control & Friends is a team of authorized and trained volunteers ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... is condemning "scam operations" carried out by unethical locksmith companies and is urging ... to a halt. According to Texas Premier Locksmith, these fraudulent locksmith services take ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... The medical ... holidays and winter seasons. One major study analyzing heart attacks among 138,602 people ... August of a given year. We would all agree of course–no time of year ...
(Date:12/7/2016)... Ohio (PRWEB) , ... December 07, 2016 , ... ... in the 2016 BOC Business Brilliance Awards under the Best New Product Launch ... and results achieved through user experience. , BOC Global Events & Training Group ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... 6, 2016 Anaplastic Oligoastrocytoma - Pipeline ... Direct,s latest Pharmaceutical and Healthcare disease pipeline guide ... an overview of the Anaplastic Oligoastrocytoma (Oncology) pipeline ... that forms when two types of cells in ... in number to form a mass. These brain ...
(Date:12/6/2016)...   AlloSource , one of the nation,s ... soft-tissue allografts for use in surgical procedures, recognized ... being named to the Board of Examiners for ... the Commerce Department,s National Institute of Standards and ... excellence. The Baldrige Award is the nation,s highest ...
(Date:12/6/2016)...  BTL Aesthetics today announced the release of ... ME device was effectively redesigned for more efficient, ... tissue. The result: Significantly better outcomes in abdominal ... ME versus BTL Vanquish. "We are ... patients with the most highly-advanced devices on the ...
Breaking Medicine Technology: